logo

For the Inventor, By the Inventor

Vernon Hills, IL, United States of America

Chih-hung Lee

USPTO Granted Patents = 50 

 

Average Co-Inventor Count = 5.7

ph-index = 9

Forward Citations = 213(Granted Patents)

Forward Citations (Not Self Cited) = 188(Dec 10, 2025)


Inventors with similar research interests:


Company Filing History:

goldMedal30 out of 4,179 
 
Abbott Laboratories Corporation
 patents
silverMedal20 out of 822 
 
Abbvie Inc.
 patents

Years Active: 2004-2018

Loading Chart...
Loading Chart...
Areas of Expertise:
Indole Derivatives
Indoline Derivatives
Pharmaceutical Compositions
Pain Treatment
TRPV1 Antagonists
Azaadamantane Derivatives
Vanilloid Receptor Inhibitors
Positive Allosteric Modulators
Thienopyridyl Compounds
Biaryl Substituted Compounds
Neuronal Nicotinic Receptor Ligands
Fused Azabicyclic Compounds
50 patents (USPTO):Explore Patents
1. 9983218 - Indole and indoline derivatives and methods of use thereof (2018-05-29),
2. 9625475 - Indole and indoline derivatives and methods of use thereof (2017-04-18),
3. 9186407 - Pharmaceutical compositions and their methods of use (2015-11-17),
4. 9063126 - Indole and indoline derivatives and methods of use thereof (2015-06-23),
5. 9040568 - Pharmaceutical compositions for the treatment of pain (2015-05-26),
6. 8987453 - Azaadamantane derivatives and methods of use (2015-03-24),
7. 8940762 - Methods for treating pain (2015-01-27),
8. 8853241 - Biaryl substituted azabicyclic alkane derivatives (2014-10-07),
9. 8815930 - Compounds that inhibit TRPV1 and uses thereof (2014-08-26),
10. 8802711 - TRPV1 antagonists (2014-08-12),
11. 8778959 - AZA-bridged ring-fused indoles and indolines (2014-07-15),
12. 8598220 - Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof (2013-12-03),
13. 8536221 - Amide derivatives as positive allosteric modulators and methods of use thereof (2013-09-17),
14. 8524703 - Bridgehead amine ring-fused indoles and indolines (2013-09-03),
15. 8501769 - Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof (2013-08-06),

Title: Innovations by Chih-hung Lee in Drug Development

Introduction

Chih-hung Lee, based in Vernon Hills, IL, is a prominent inventor with an impressive portfolio of 50 patents. His work focuses on the development of innovative compounds aimed at treating various disease conditions, showcasing his commitment to advancing pharmaceutical science.

Latest Patents

Among his notable contributions, Chih-hung Lee's latest patents include groundbreaking research on indole and indoline derivatives. These patents detail compounds of specific formulas (I, II, III, IV, V, or VI) which play crucial roles in medicinal chemistry. The applications describe methods for using these derivatives, emphasizing their potential in treating various disease conditions through compositions that enhance their efficacy. These advancements not only contribute to the field of pharmaceuticals but also offer new avenues for therapeutic discoveries.

Career Highlights

Throughout his career, Chih-hung Lee has worked with prestigious organizations such as Abbott Laboratories Corporation and AbbVie Inc., leading teams in the pursuit of innovative health solutions. His extensive research and development efforts have significantly impacted drug formulation and discovery, establishing him as a key figure in the pharmaceutical industry.

Collaborations

Chih-hung Lee has collaborated with esteemed coworkers including Arthur Gomtsyan and John R. Koenig. Their joint efforts have enriched the research environment, facilitating the exchange of ideas and fostering advancements in drug development.

Conclusion

Chih-hung Lee's contributions to the field through his patents and collaborations underscore the importance of innovation in healthcare. His ongoing research into indole and indoline derivatives showcases the potential for novel therapies that could improve patient outcomes, reaffirming his status as an invaluable asset in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…